Experience

Davis Polk advised the joint book-running managers in connection with a $325 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed…

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which included the exercise in full by the underwriters of their option to…

Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of Insulet Corporation. The offering resulted in approximately $500…

Davis Polk the initial purchasers in connection with a Rule 144A offering by Cantel Medical Corp. of $140 million principal amount of 3.250% convertible senior notes due 2025. Cantel’s…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a SEC-registered follow-on offering of 4,573,863 shares of common stock…

Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $1.05 billion aggregate principal amount of its 0.250%…

Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering program by Affimed N.V. of up to $50 million gross sales price of…

Davis Polk advised the joint book-running managers, in connection with an SEC-registered offering by Zoetis Inc. of $750 million aggregate principal amount of its 2.000% senior notes due…

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…